Crossmark

Bispecific Antibody Emicizumab for Haemophilia A: A Breakthrough for Patients with Inhibitors

Crossref DOI link: https://doi.org/10.1007/s40259-018-0315-0

Published Online: 2018-11-14

Published Print: 2018-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mahlangu, Johnny N. https://orcid.org/0000-0001-5781-7669
License Information

Text and Data Mining valid from 2018-11-14
More Information

Article History

First Online: 14 November 2018

Compliance with ethical standards

:

: The preparation of this article required no external funding.

: JN Mahlangu declares no relevant conflicts of interest.